NewAmsterdam Pharma (NAMS) Depreciation & Amortization (CF) (2023 - 2026)

NewAmsterdam Pharma has disclosed Depreciation & Amortization (CF) across 4 years of filings, most recently posting $62000.0 for Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $62000.0, up 19.23% year-over-year; the trailing twelve-month figure through Mar 2026 was $230000.0 (up 53.33% YoY), and the FY2025 annual result was $220000.0, up 94.69% from the prior year.
• Depreciation & Amortization (CF) came in at $62000.0 for Q1 2026 at NewAmsterdam Pharma, up from $59000.0 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $64000.0 in Q3 2025 to a low of $9000.0 in Q1 2023.
• The 4-year median for Depreciation & Amortization (CF) is $36500.0 (2024), against an average of $35916.7.
• Across the five-year window, Depreciation & Amortization (CF) jumped 292.31% in 2024 and climbed 15.69% in 2025, its largest moves.
• NewAmsterdam Pharma's Depreciation & Amortization (CF) stood at $13000.0 in 2023, then surged by 292.31% to $51000.0 in 2024, then gained by 15.69% to $59000.0 in 2025, then rose by 5.08% to $62000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $62000.0 (Q1 2026), $59000.0 (Q4 2025), and $64000.0 (Q3 2025), per Business Quant data.